# PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

> **NCT04907370** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 532 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** PD-1 blocking antibody
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin (80mg/m2)
- **DRUG:** Cisplatin (100mg/m2)
- **RADIATION:** Intensity-modulated radiotherapy

## Key facts

- **NCT ID:** NCT04907370
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 532 (ACTUAL)
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04907370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04907370, "PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04907370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*